Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma
International Journal of Cancer, Volume 111, No. 1, Year 2004
Notification
URL copied to clipboard!
Description
Surgery and radiotherapy are standard treatments for early oral squamous cell carcinoma, both resulting in good tumour control. However, neither of these modalities is without consequent functional or cosmetic impairment, and there are patients in whom both are contraindicated. Furthermore, there is a significant risk of metachronous tumours developing in the oral cavity, and salvage or retreatment with either surgery or radiotherapy poses difficulties. Photodynamic therapy (PDT) offers the potential for improved functional and cosmetic outcomes, while achieving comparable tumour control. We conducted an open-label, multicentre study to assess the efficacy and safety of metatetrahydroxyphenylchlorin (mTHPC) in patients with early oral cancer. One hundred twenty-one patients received intravenously administered mTHPC, followed 96 hr later by illumination of the tumour surface with 652 nm laser light. Of these patients, 114 were protocol compliant. A complete tumour response was achieved in 85% of protocol-compliant patients (97 of 114 patients). A complete response was maintained in 85% of responders at 1 year and in 77% at 2 years. One- and 2-year actuarial survival rates were 89% and 75%, respectively. In the opinion of the investigators, tumour clearance was accompanied by excellent cosmetic and functional results, without impact on the patients' performance status. Mild-to-moderate pain at the treatment site, a recognised side effect of PDT in the oral cavity, was reported by 82% of patients but was manageable with appropriate analgesia. Mild-to-moderate skin photosensitivity reactions were reported for 13% of patients. mTHPC offers an effective alternative treatment for early oral squamous cell carcinoma. It is associated with excellent functional and cosmetic results and can be used in conjunction with other standard therapies. © 2004 Wiley-Liss, Inc.
Authors & Co-Authors
Hopper, Colin
United Kingdom, London
Eastman Dental Institute
United Kingdom, London
University College London Hospitals Nhs Foundation Trust
Kübler, Alexander Christian
Germany, Koln
Uniklinik Köln
Lewis, Harry
United Kingdom, Dundonald
Ulster Hospital
Tan, I. Bing
Netherlands, Amsterdam
The Netherlands Cancer Institute
Putnam, Graham D.
United Kingdom, Carlisle
Cumberland Infirmary
Patrice, T.
France, Nantes
Clin. Orl
Beauvillain, C.
France, Nantes
Clin. Orl
Evensen, J.
Norway, Oslo
Rikshospitalet-radiumhospitalet hf
Bütow, Kürt Wilhelm
South Africa, Pretoria
University of Pretoria
Smit, Ben J.
South Africa, Tygerberg
Tygerberg Hospital
Brown, J.
United Kingdom, Liverpool
Aintree University Hospital
De Carpentier, J.
United Kingdom, Preston
Royal Preston Hospital
Carruth, J.
United Kingdom, Southampton
Southampton General Hospital
Dilkes, M.
United Kingdom, London
St Bartholomew's Hospital
Kenyon, G. S.
United Kingdom, London
St Bartholomew's Hospital
Roberts, F.
United Kingdom, Leeds
Cookridge Hospital
Sudderick, N.
United Kingdom, Guildford
Royal Surrey Hospital
Statistics
Citations: 195
Authors: 17
Affiliations: 16
Identifiers
Doi:
10.1002/ijc.20209
ISSN:
00207136
Research Areas
Cancer
Health System And Policy